Key Highlights
- Total Revenue was USD 123.1 million; adjusted gross Margin was 72%.
- Adjusted Net Income was USD 8.6 million.
- The company reported over 32,100 exome and genome tests.
- Blended average reimbursement was USD 3,436, up 5% sequentially.
GeneDx Holdings Corp. (NASDAQ:WGS) reported third quarter 2026 total revenue of USD 123.1 million, including USD 110.4 million of exome and genome revenue, which was up USD 10 million sequentially. Reported EPS was negative USD 0.41 and revenue was USD 123.10 million, compared with estimates of EPS of USD 0.07 and revenue of USD 122.93 million.
Adjusted gross margin expanded from 69% in the first quarter to 70% in the second and 72% in the third. Adjusted net income improved from a loss of USD 8.2 million in the first quarter to near break even in the second and USD 8.6 million in the third. The company reported over 32,100 exome and genome tests.
Reimbursement and Revenue Cycle
Management said revenue cycle management was its number one priority and cited progress. The blended average reimbursement rate was USD 3,436, up 5% from USD 3,258 in the second quarter, reflecting improved genome collections and a mix shift toward the exome line.
Management said it found that 62% of exome and genome denials were administrative and procedural in nature, while the remaining 38% relate to subjective clinical necessity disputes or patients not covered by payer policies. In the quarter, it aligned genome testing workflows to collect more payer required documentation before testing begins. Management noted that collecting documentation upfront can extend the time between accession and the start of testing, with accessions growing 28% while reported Volume grew 25%.
The underlying outpatient genome collection rate was 36%, up 400 basis points from 32% in the prior quarter. The exome collection rate was approximately 32%, flat with the second quarter. Management described the second quarter as interrogating processes with third party experts, the third quarter as validating the plan and designing the future architecture, and the fourth quarter and early 2027 as implementation.
Mix and Coverage
Within the portfolio, 92% of volume was outpatient insurance based, with Medicaid, the largest payer segment, at 48%. Genome was 26% of outpatient insurance based volume, down from 32% in the second quarter. Genome cost per test has come down 43% from last year.
Positive exome policies are in place for 98% of commercial lives and positive genome coverage for 88%. Carelon expanded its policy to approximately 56 million lives in June. Medicaid covers exome in 37 states and genome in 25 states, up from 23 in the second quarter. Approximately 82% of outpatient genome volume was submitted to payers with an active positive coverage policy, up from 67% the prior quarter. Management said the general pediatrician segment is the one it cited as driving greater unit volume growth in 2027 than all other segments.
Guidance Updates
Management raised full year adjusted gross margin guidance to approximately 71% and adjusted net income guidance to at least USD 12 million, and reaffirmed full year revenue guidance of USD 475 million to USD 490 million. It adjusted full year exome and genome volume growth to at least 28% and revenue growth to at least 17%.
For the fourth quarter, management cited average reimbursement of approximately USD 3,500 a test, adjusted gross margin of at least 71%, adjusted net income of approximately USD 12 million, total revenue of at least USD 135 million, and exome and genome revenue of USD 121 million on volume of 34,500 tests. Approximately 85% of total revenue is insurance based.
Reimbursement and Guidance
GeneDx reported over 32,100 exome and genome tests and blended average reimbursement of USD 3,436. Management cited the denial root cause split, collection rates, payer coverage figures and its guidance ranges.






Please wait processing your request...